IA
BMRN icon

IFG Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

IFG Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1K Buy
+212
New +$11.6K ﹤0.01% 1787
2018
Q1 		– Sell
-2,394
Closed -$213K – 335
2017
Q4 		$213K Buy
+2,394
New +$208K 0.05% 306

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

IFG Advisory's BMRN Position: Q2 2026 in Review

IFG Advisory opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 212 shares worth $12.1K. The stake represents ﹤0.01% of the portfolio and ranks #1787 among its holdings. This is a return to the name: IFG Advisory previously reported a position in BMRN as recently as Q4 2017.

IFG Advisory first reported a position in BMRN in Q4 2017 and has held it in 2 quarters since. The position peaked at $213K in Q4 2017. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • IFG Advisory held 212 shares of BioMarin Pharmaceuticals worth $12.1K as of Q2 2026.
  • BioMarin Pharmaceuticals was a new IFG Advisory position in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of IFG Advisory's portfolio in Q2 2026, its #1787 holding.
  • IFG Advisory first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 2 quarters since.
  • IFG Advisory's BioMarin Pharmaceuticals position peaked at $213K in Q4 2017.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on IFG Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.